Classification of prostate cancer into distinct molecular subtypes, including mutually exclusive ETS-gene-fusion-positive and SPINK1-overexpressing, CHD1-loss cancers, could allow stratification of patients for different management strategies.
TOX3 was expressed across multiple molecular subtypes, including luminal, molecular apocrine, and normal-like.
We also extended the analysis of Toca-1 levels to the major molecular subtypes, including luminal, HER2 and TNBC.
The expression level and cellular localization of CXCR4 in human breast tumours have also been analyzed in view of its molecular subtypes, including triple-negative breast cancers (TNBC), luminal subtypes, and HER2-positive breast cancers, via IHC.
Hierarchical clustering analysis of this data set using the ~1,900 intrinsic gene list of Parker et al. [ 9] identified the major intrinsic molecular subtypes, including the claudin-low subtype.
There was no significant difference in the expression levels of Bcl-2 transcripts in the four breast cancer molecular subtypes, including up-regulation, down-regulation and no change (P = 0.282).
A recent gene expression analysis of TNBC identified at least six tumor molecular subtypes, including a mesenchymal-like subset that was highly sensitive to PI3K/mTOR inhibitors in vitro and in vivo[ 26].
In a previous study on the Tp53-null mouse mammary tumour model, researchers demonstrated that the generated tumours exhibit considerable heterogeneity and can be classified by transcript profiling into a variety of molecular subtypes, including one luminal, one claudin-low and two basal-like subtypes [ 22].
The heterogeneity of breast tumors is mirrored in the identification of at least five molecular subtypes including basal-like, luminal A, luminal B, HER2-enriched and normal-like, which are believed to originate from different cell types and follow different progression pathways [ 1, 2].
In this study, we used Affymetrix Human Exon 1.0 ST Array (HuEx) to measure exon expression levels in 47 neuroblastoma samples of different clinical stages and molecular subtypes including stage 1 with normal MYCN copy number (1-), stage 4 with MYCN amplification (4+) or normal MYCN copy number (4-).
